MyX Therapeutics was created as a spin-out from AmorChem to commercialize MyX-001, a patented biodegradable muco-adhesive nanoparticle delivery platform for sustained drug release in ophthalmic and other mucosal routes. The platform can be tuned to maximize drug loading and provide sustained release, potentially enabling reduced dosing frequency (examples cited: 1x/day or 2x/week), improved hydration/lubrication and lower required API doses based on initial animal models. Targeted routes include ophthalmic, sublingual, intranasal, vaginal and gastrointestinal deliveries, with an initial commercial focus on ocular diseases in both animal and human health. AmorChem transferred all rights to the MyX-001 technology to MyX Therapeutics and provided a $450,000 seed investment to help the company clinch its first deals with commercial partners. Management appointments at launch include Gregory L. White as CEO, Dr. Frank Gu as Chief Scientific Officer and Véronique Bougie as COO; the technology was developed by University of Waterloo researchers Dr. Frank Gu, Dr. Lyndon Jones and Dr. Sandy Liu. MyX plans to pursue a product-development licensing partnership business model and to expand applications of the platform, including uses unrelated to health.

Total raised

$0M

Funding rounds

1

Latest round

Seed

Latest activity

Dec 2018